RxDoctor Payments Data

Alfred Denio, MD

Rheumatology · Danville, PANPI 1972584001

Payments from drug & device makers

$15,340in general payments, 2019–2025

Across 31 payments — averaging $494.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • E.r. Squibb & Sons, L.L.C.$5K
  • Johnson & Johnson$4K
  • Amgen$213
  • UCB, Inc.$142
  • Sobi, Inc$120
  • plus $100 from 1 others

What the payments were for

  • Consulting fees$7,66950%
  • Speaking & faculty fees$5,60037%
  • Travel & lodging$9746%
  • Food & beverage$9976%
  • Education$1001%

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,340 in reported general payments places this provider in the 70th percentile of 351 rheumatology providers in Pennsylvania.

See all rheumatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$59,772
Medicare patients
657
Services billed
1,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab100$720,161
Enbrel SureclickEtanercept40$288,425
XeljanzTofacitinib Citrate28$159,096
RinvoqUpadacitinib23$142,035
EnbrelEtanercept16$116,409
Humira(Cf) PenAdalimumab13$86,068
ActemraTocilizumab20$73,900
KevzaraSarilumab18$73,538
Orencia ClickjectAbatacept12$67,113
KineretAnakinra12$65,727
ForteoTeriparatide11$46,717
Hydroxychloroquine Sulfate254$9,839
Leflunomide134$7,189
MethotrexateMethotrexate Sodium320$6,686
Mycophenolate Mofetil16$5,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$5,773$142,03523 claims
AmgenEnbrel$213$116,40916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 351 rheumatology providers in Pennsylvania.

Other rheumatology in Danville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →